Characteristics of Ongoing Clinical Trials of Psychogenic Substances for Psychiatric Disorders.
Journal of clinical psychopharmacology John L Havlik, Sayana Isaac, Pralahad Raman et al.
As of late 2024, 181 ongoing clinical trials of psychogenic substances for psychiatric disorders are registered on ClinicalTrials.gov. Most are in phase 2 (51.4%) or phase 1 (18.2%), with psilocybin (35.4%) and ketamine (33.7%) the most studied compounds. Trials concentrate at a few leading academic institutions. Over 81% list their funding source as "other," and 86% of those are sponsored by universities or university-affiliated institutions. Blinding is not reported in 38.7% of trials. Major depressive disorder (51.9%), posttraumatic stress disorder (21.0%), and alcohol use disorder (11.6%) are the primary conditions targeted. The lack of clear funding disclosure indicates a need for greater transparency.